GenoMed to be awarded new patent, for treating acute kidney failure without dialysis

GenoMed announced today that the US Patent Office has allowed claims and will be following up with an issued patent shortly on the Company's protocol to treat acute kidney failure with a drug rather than the dialysis machine.

Currently, patients with acute kidney failure are placed on the kidney machine in a hospital until their own kidney function improves. The older a person is, the less likely their kidneys are to recover, and the longer the patient has to stay on kidney dialysis. Acute kidney failure carries a 50% risk of dying, and it involves a much longer and more expensive hospitalization.

GenoMed's treatment makes use of an already existing, generic drug to promote recovery of kidney function, usually within 24 hours. In pilot studies, more than 70% of adults, including those with hepatorenal syndrome, and newborns have been spared kidney dialysis. A larger trial is being planned for publication.

GenoMed's treatment is ideal where access to kidney dialysis is scarce, e.g. after an earthquake, on the battlefield, or in the Third World. First World countries interested in cutting healthcare costs and improving the atrocious mortality of acute renal failure might also be interested in GenoMed's approach.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults